How Will Pfizer Leverage External Innovation After BioNTech Jackpot?

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

NEW YORK CITY - MAY 2015: Metal plate logo of Pfizer in his headquarters building. Pfizer is an American multinational pharmaceutical corporation, one of the world's largest pharmaceutical companies.

The past two years have been transformational for Pfizer Inc., thanks to its partnership with German biotech firm BioNTech SE. Uwe Schoenbeck, senior vice president and chief scientific officer, external science and innovation at Pfizer, spoke to In Vivo about how external innovation and internal agility are key to the company’s future success.

Heading into 2022, Pfizer – now a household name the world over thanks to the success of its COVID-19 vaccine...

More from Outlook Archive

More from Outlook